uploads/2018/03/Gleevec.png

How Did Novartis’s Gleevec, Tasigna, and Sandostatin Perform in 4Q17?

By

Updated

Gleevec revenue trends

In 4Q17, Novartis’s (NVS) Gleevec generated revenues of $448 million, which reflected a ~41% decline on a year-over-year (or YoY) basis and 1% growth quarter-over-quarter. In fiscal 2017, Gleevec generated revenues of $1.9 billion compared to $3.3 billion in 2016, which reflected a ~42% decline on a YoY basis.

The availability of generic imatinib in most major markets was primarily attributed to the continued decline of revenues during 2017 and 4Q17. Gleevec is used for the treatment of individuals with Philadelphia chromosome-positive chronic myeloid leukemia (or Ph+ CML) and KIT-positive gastrointestinal tumors that cannot be removed surgically.

Article continues below advertisement

Tasigna revenue trends

In 4Q17, Tasigna generated revenues of $485 million compared to $458 million in 4Q16, which reflected ~6% growth on a YoY basis and 1% growth quarter-over-quarter. In fiscal 2017, Tasigna generated revenues of $1.8 billion compared to $1.7 billion in 2016, which reflected ~6% growth on a YoY basis.

The sales growth in the US market primarily attributed to the solid growth of Tasigna in 4Q17. Tasigna finds its use in the treatment of Ph+ CML in chronic phase and in adults with Ph+ CML who were resistant to at least one prior therapy including imatinib (Gleevec). In the Ph+ CML drugs market, Novartis’s Tasigna and Gleevec compete with (PFE) Bosulif, Bristol-Myers Squibb’s (BMY) Sprycel, and Takeda Pharmaceuticals’ (TKPYY) Iclusig.

Sandostatin revenue trends

In 4Q17, Sandostatin generated revenues of $421 million, which reflected ~3% growth on a YoY basis and 5% growth quarter-over-quarter. In fiscal 2017, Sandostatin generated revenues of $1.61 billion compared to $1.65 billion in 2016, a ~2% decline on a YoY basis.

The sales growth in the emerging markets primarily led to the revenue growth of Sandostatin. Sandostatin is used for the treatment of acromegaly.

Advertisement

More From Market Realist